Pilot Study of Maraviroc/Raltegravir for Naive HIV-1 Patients

Update Il y a 4 ans
Reference: NCT01291459

Woman and Man

  • | Country :
  • France
  • | organs :
  • -
  • | Specialty :
  • -


Background and Rationale Raltegravir and Maraviroc, the first in class of 2 new families of antiretroviral drugs have demonstrated a high potency in treatment experienced and naive patients. Both drugs appeared well tolerated with low metabolic toxicity. No data are currently available concerning the combination of these 2 drugs. Hypothesis Maraviroc + Raltegravir should be potent enough to maintain virological efficacy in naive patients infected by CCR5 HIV-1 previously treated for 6 months with a Maraviroc-Raltegravir-Tenofovir-Emtricitabine combination.

Inclusion criteria

  • HIV